Core Viewpoint - KBC Group SA has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. KBC Group's Earnings Outlook - The recent upgrade for KBC Group reflects an improvement in its underlying business, which is expected to drive the stock price higher as investors recognize this trend [5]. - For the fiscal year ending December 2025, KBC Group is projected to earn $5.03 per share, with a 9.5% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - KBC Group's upgrade to Zacks Rank 1 places it in the top 5% of stocks covered by Zacks, indicating strong potential for market-beating returns in the near term [10].

Rigel Pharmaceuticals (RIGL) has been beaten down lately with too much selling pressure. While the stock has lost 27% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and chang ...

Global Partners LP's recent purchase of 5,000 shares indicates a strong belief in the company's future growth.Zacks Investment Research highlights GLP as potentially undervalued, making it attractive to value investors.With a market capitalization of approximately $1.7 billion, GLP remains a significant player in the Oils-Energy sector.Global Partners LP (NYSE:GLP) is a key player in the Oils-Energy sector, which includes 240 companies and is ranked #14 in the Zacks Sector Rank. The company is involved in t ...

Core Viewpoint - VEON Ltd. has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to calculate the fair value of a company's shares, leading to buying or selling actions that affect stock prices [3]. VEON's Earnings Outlook - The recent rating upgrade for VEON indicates an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - Analysts have raised their earnings estimates for VEON, with the Zacks Consensus Estimate increasing by 112% over the past three months [7]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - The upgrade of VEON to a Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for near-term price increases [9].

Core Viewpoint - Hillman Solutions Corp. (HLMN) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - For Hillman Solutions Corp., the recent upgrade reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [5][10]. Earnings Estimate Revisions - Hillman Solutions Corp. is projected to earn $0.55 per share for the fiscal year ending December 2025, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for Hillman Solutions Corp. has increased by 2.2%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, highlighting their potential for market-beating returns [9][10]. - Hillman Solutions Corp.'s upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a favorable outlook for the stock in the near term [10].

Core Viewpoint - Collegium Pharmaceutical (COLL) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for Collegium Pharmaceutical reflects an improvement in its underlying business, suggesting that investors may push the stock price higher due to this positive trend [5][10]. - The Zacks Consensus Estimate for Collegium Pharmaceutical indicates expected earnings of $7.03 per share for the fiscal year ending December 2025, with a 1.8% increase in estimates over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, positioning Collegium Pharmaceutical among the best candidates for potential market-beating returns [9][10].

Core Viewpoint - CAMP4 Therapeutics Corporation (CAMP) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - For CAMP, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to a higher stock price [5]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The upgrade of CAMP to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating superior earnings estimate revisions and potential for market-beating returns [10]. Earnings Estimate Details - CAMP is projected to earn -$1.71 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for CAMP has increased by 31%, reflecting analysts' growing confidence in the company's earnings potential [8].

Core Viewpoint - Atlas Copco AB has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Atlas Copco suggest an improvement in the company's underlying business, likely leading to increased stock prices [5]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns for top-rated stocks [7][9]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [10]. Earnings Estimate Details - Atlas Copco is projected to earn $0.58 per share for the fiscal year ending December 2025, with a 0.9% increase in the Zacks Consensus Estimate over the past three months [8].

Core Viewpoint - Analyst recommendations play a significant role in influencing stock prices, but their reliability is questionable, particularly for XPeng Inc. (XPEV) [1][5][10] Group 1: Analyst Recommendations - XPeng has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy, based on 20 brokerage firms [2][4] - Out of the 20 recommendations, 11 are Strong Buy and 2 are Buy, representing 55% and 10% of total recommendations respectively [2] Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the highest price increase potential [5] - Analysts often exhibit a positive bias due to the vested interests of brokerage firms, leading to a disproportionate number of favorable ratings [6][10] - For every "Strong Sell" recommendation, there are five "Strong Buy" recommendations, suggesting a misalignment of interests with retail investors [6] Group 3: Zacks Rank vs. ABR - The Zacks Rank, which is based on earnings estimate revisions, is a more reliable indicator of near-term stock price performance compared to ABR [8][11] - Zacks Rank is displayed in whole numbers (1 to 5) and is updated more frequently, reflecting timely changes in earnings estimates [9][12] - XPeng currently holds a Zacks Rank of 3 (Hold), indicating cautious sentiment despite the favorable ABR [13][14]

Core Viewpoint - The article discusses the reliability of brokerage recommendations and their influence on stock prices, specifically focusing on ATI's average brokerage recommendation (ABR) and its implications for investors [1][5]. Group 1: Brokerage Recommendations - ATI has an average brokerage recommendation (ABR) of 1.50, indicating a consensus between Strong Buy and Buy, based on recommendations from 12 brokerage firms [2]. - Out of the 12 recommendations, 9 are classified as Strong Buy, accounting for 75% of the total recommendations [2]. - Despite the positive ABR, the article cautions against making investment decisions solely based on this metric, as studies show limited success of brokerage recommendations in predicting stock price increases [5]. Group 2: Analyst Bias and Zacks Rank - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, with five "Strong Buy" recommendations for every "Strong Sell" recommendation, which may mislead investors [6][10]. - The Zacks Rank, a proprietary stock rating tool, categorizes stocks based on earnings estimate revisions and is considered a more effective indicator of near-term stock price performance compared to ABR [8][11]. - The Zacks Rank is updated more frequently than ABR, reflecting timely changes in earnings estimates, which can provide better insights into future price movements [12]. Group 3: ATI's Earnings Estimates - The Zacks Consensus Estimate for ATI's earnings for the current year remains unchanged at $3.06, suggesting stable analyst views on the company's earnings prospects [13]. - Due to the unchanged consensus estimate and other factors, ATI holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [14].